Dianthus Therapeutics (DNTH) Restructuring Costs (2023)
Dianthus Therapeutics (DNTH) posted quarterly Restructuring Costs of $1.9 million for Q2 2023, down 89.35% quarter-over-quarter from $18.0 million in Q1 2023.
Dianthus Therapeutics (DNTH) Restructuring Costs (2023) Analysis & Trends
Dianthus Therapeutics' Restructuring Costs history runs 1 years deep, the most recent figure standing at $1.9 million for Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Dianthus Therapeutics | 4.97 Bn | 4.57 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 1.92 Mn |
| Mar 31, 2023 | 18.00 Mn |